Citations

Clear

48 citation(s) found for "Lin, Nancy U".

Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival
Sperduto, Paul W. , Li, Jing , Cagney, Daniel , Aizer, Ayal A. , Nesbit, Eric , Chan, Jason W., Breen, Will, Brown, Paul D. , Shi, Diana D. , Soliman, Hany , Sahgal, Arjun , Shanley, Ryan , Sperduto, William , Everett, Ashlyn S. , Boggs, Drexell H. , Masucci, Laura , Plichta, Kristin A. , Buatti, John M. , Jain, Supriya , Gaspar, Laurie E., Wu, Cheng–Chia , Wang, Tony J. C. , Bryant, John , Chuong, Michael D. , Chiang, Veronica , Nakano, Toshimichi , Shi, Diana , Buatti, John M , Wang, Tony J C , Mesko, Shane , Lin, Nancy U. , Kruser, Tim J. , Braunstein, Steve , Lee, Jessica , Kirkpatrick, John P. , Shih, Helen A. , Lou, Emil , Roberge, David , Remick, Jill S. , Bryant, John, Yu, James B. , Aoyama, Hidefumi , Mehta, Minesh P.

Mayo Clinic

Neuro-Oncology | February 6, 2020 | Volume: 22 | Issue: 9 | Pages: 1359-1367

10.1093/neuonc/noaa025 | PMID 32034917 Get It

Abstract Background Breast cancer treatment is based on estrogen receptors (ERs), progesterone receptors (PRs), and human epidermal growth factor receptor 2 (HER2). At the time of metastasis, receptor status can be discordant from that at initial diagnosis. The purpose of this study was to determine the incidence of discordance and its effect on survival and subsequent treatment in patients with breast cancer brain metastases (BCBM). Methods A retrospective database of 316 patients who underwent craniotomy for BCBM between 2006 and 2017 was created. Discordance was considered present if the ER, PR, or HER2 status differed between the primary tumor and the BCBM. Results The overall receptor discordance rate was 132/316 (42%), and the subtype discordance rate was 100/316 (32%). Hormone receptors (HR, either ER or PR) were gained in 40/160 (25%) patients with HR-negative primary tumors. HER2 was gained in 22/173 (13%) patients with HER2-negative primary tumors. Subsequent treatment was not adjusted for most patients who gained receptors—nonetheless, median survival (MS) improved but did not reach statistical significance (HR, 17–28 mo, P = 0.12; HER2, 15–19 mo, P = 0.39). MS for patients who lost receptors was worse (HR, 27–18 mo, P = 0.02; HER2, 30–18 mo, P = 0.08). Conclusions Receptor discordance between primary tumor and BCBM is common, adversely affects survival if receptors are lost, and represents a missed opportunity for use of effective treatments if receptors are gained. Receptor analysis of BCBM is indicated when clinically appropriate. Treatment should be adjusted accordingly. Key Points 1. Receptor discordance alters subtype in 32% of BCBM patients. 2. The frequency of receptor gain for HR and HER2 was 25% and 13%, respectively. 3. If receptors are lost, survival suffers. If receptors are gained, consider targeted treatment.
INNV-33. BARRIERS TO ACCRUAL AND ENROLLMENT IN BRAIN TUMOR TRIALS
Lee, Eudocia Q. , Chukwueke, Ugonma , Hervey‐Jumper, Shawn L. , DeGroot, John, Leone, Pablo, Chang, Susan M. , Arons, David, Oliver, Kathy , Verble, Kay, Musella, Al , Willmarth, Nicole E. , Doherty, Lisa, Gaffey, Sarah, Halkin, Thomas, Friday, Bret Edward Buckley, Fouladi, Maryam , Macdonald, David R., Peñas-Prado, Marta , Vogelbaum, Michael A. , Sahebjam, Solmaz , Sandak, David, Reardon, David A. , Wen, Patrick Y. , Armstrong, Terri S. , Alexander, Brian M. , Bates, Amanda, Galanis, Evanthia , Lin, Nancy U. , Mehta, Minesh P. , Bent, Martin J. van den , Weller, Michael , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology | November 11, 2019 | Volume: 21 | Issue: Supplement_6 | Pages: vi137-vi137

10.1093/neuonc/noz175.574 Get It

Abstract BACKGROUND A major impediment to improving neuro-oncology outcomes is poor clinical trial accrual. METHODS We convened a multi-stakeholder group including Society for Neuro-Oncology, Response Assessment in Neuro-Oncology, patient advocacy groups, clinical trial cooperative groups, and other partners to determine how we can improve trial accrual. RESULTS We described selected factors contributing to poor trial accrual and possible solutions. We focused on patient and community factors, disparities, physician and provider factors, clinical trial factors, and site and organizational factors CONCLUSIONS We will implement strategies with the intent to double accrual to neuro-oncology trials over the next 5 years.
Barriers to accrual and enrollment in brain tumor trials
Lee, Eudocia Q. , Chukwueke, Ugonma , Hervey‐Jumper, Shawn L. , Leone, José Pablo , Chang, Susan M. , Arons, David, Oliver, Kathy , Verble, Kay, Musella, Al , Willmarth, Nicole E. , Doherty, Lisa, Gaffey, Sarah, Halkin, Thomas, Friday, Bret Edward Buckley, Fouladi, Maryam , Macdonald, David R., Peñas-Prado, Marta , Vogelbaum, Michael A. , Sahebjam, Solmaz , Sandak, David, Bent, Martin J. van den , Weller, Michael , Reardon, David A. , Wen, Patrick Y. , Galanis, Evanthia , Weller, Michael , van den Bent, Martin J , Groot, John de , Armstrong, Terri S. , Chang, Susan Marina , Alexander, Brian M. , Bates, Amanda, Lin, Nancy U. , Mehta, Minesh P. , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology | June 7, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/neuonc/noz104 | PMID 31175826 Get It

Abstract Many factors contribute to the poor survival of malignant brain tumor patients, some of which are not easily remedied. However, one contributor to the lack of progress that may be modifiable is poor clinical trial accrual. Surveys of brain tumor patients and neuro-oncology providers suggest that clinicians do a poor job of discussing clinical trials with patients and referring patients for clinical trials. Yet, data from the Cancer Action Network of the American Cancer Society suggest that most eligible oncology patients asked to enroll on a clinical trial will agree to do so. To this end, the Society for Neuro-Oncology (SNO) in collaboration with the Response Assessment in Neuro-Oncology (RANO) Working Group, patient advocacy groups, clinical trial cooperative groups, including the Adult Brain Tumor Consortium (ABTC), and other partners are working together with the intent to double clinical trial accrual over the next 5 years. Here we describe the factors contributing to poor clinical trial accrual in neuro-oncology and offer possible solutions.
Barriers to accrual and enrollment in brain tumor trials.
Lee, Eudocia Q. , Chukwueke, Ugonma , Hervey‐Jumper, Shawn L. , Groot, John Frederick De, Leone, José Pablo , Chang, Susan M. , Arons, David, Oliver, Kathy , Friday, Bret Edward Buckley, Penas‐Prado, Marta, Vogelbaum, Michael A. , Sahebjam, Solmaz , Bent, Martin J. van den , Reardon, David A. , Wen, Patrick Y. , van den Bent, Martin J , Armstrong, Terri S. , Chang, Susan Marina , Galanis, Evanthia , Lin, Nancy U. , Mehta, Minesh P. , Peñas-Prado, Marta , Weller, Michael , Wen, Patrick Yung

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: 2024-2024

10.1200/jco.2019.37.15_suppl.2024 Get It

2024 Background: A major impediment to improving neuro-oncology outcomes is poor clinical trial accrual. Methods: We convened a multi-stakeholder group including Society for Neuro-Oncology, Response Assessment in Neuro-Oncology, patient advocacy groups, clinical trial cooperative groups, and other partners to determine how we can improve trial accrual. Results: We describe selected factors contributing to poor trial accrual and possible solutions. Conclusions: We will implement strategies with the intent to double trial accrual over the next 5 years. [Table: see text]
RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis
Isaac, Gaëlle, Vries, Elisabeth G.E. de , Bogaerts, Jan , Chen, Alice P. , Dancey, Janet, Ford, Robert, Gwyther, Stephen J., Hoekstra, Otto S. , Huang, Erich P. , Liu, Yan , Mandrekar, Sumithra J. , Schwartz, Lawrence H., Shankar, Lalitha , Therasse, Patrick, Group, on behalf of the RECIST Working, de Vries, Elisabeth G E , Litière, Saskia , Lin, Nancy U. , Seymour, Lesley , Group, on behalf of the RECIST Working

Mayo Clinic

Journal of Clinical Oncology | March 12, 2019 | Volume: 37 | Issue: 13 | Pages: 1102-1110

10.1200/jco.18.01100 | PMID 30860949 Get It

PURPOSE The mode of action of targeted cancer agents (TCAs) differs from classic chemotherapy, which leads to concerns about the role of RECIST in evaluating tumor response in trials with TCAs. We investigated the performance of RECIST using a pooled database from 50 clinical trials with at least one TCA. METHODS We examined the impact of the number of target lesions (TLs) on within-patient variability of tumor response. The prognostic effect of TL response (at 12 weeks or on study on the basis of a maximum five TLs) on survival was studied through landmark and time-dependent Cox models adjusted for baseline tumor load, occurrence of new lesions, or unequivocal progression of nontarget disease. RESULTS Data were obtained from 23,259 patients with cancer (36% lung, 28% colorectal, 11% breast, and 25% other); 15,620 received TCAs, predominantly transduction or angiogenesis inhibitors, as a single agent (37%), combined with other TCAs (7%), or as chemotherapy (56%); 28% received chemotherapy only; and 5% received best supportive care or placebo. A total of 17,222 patients contributed to the analyses. Within-patient variability decreased with increasing number of TLs, similarly for TCAs (with/without chemotherapy) and chemotherapy only. Mixed responses occurred proportionally in all treatment classes. Landmark analyses showed an ordinal relationship between percentage change from baseline to 12 weeks and overall survival, and demonstrated a clear distinction between tumor shrinkage and progressive disease according to RECIST. Time-dependent analysis showed no marked improvement in the ability to predict survival on the basis of TL tumor growth compared with nontarget progression or new lesion occurrence, regardless of treatment. Similar results were seen for major tumor types and different classes of TCAs. CONCLUSION This work reinforces that RECIST version 1.1 perform well for response assessment of TCAs.
TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases
Gelman, Rebecca , Anders, Carey K. , Melisko, Michelle , Parsons, Heather A. , Cropp, Anne B., Silvestri, Kelly M., Cotter, Christine M., Componeschi, Kathryn P., Marte, Juan M., Connolly, Roisín M. , Poznak, Catherine Van , Blackwell, Kimberly , Puhalla, Shannon L. , Jankowitz, Rachel C. , Ibrahim, Nuhad K. , Moynihan, Timothy J. , O’Sullivan, Ciara C. , Nangia, Julie R. , Pohlmann, Paula R. , Burns, Robyn, Rimawi, Mothaffar F. , Krop, Ian E. , O'Sullivan, Ciara C, Rimawi, Mothaffar , Freedman, Rachel A. , Moy, Beverly , Smith, Karen L. , Niravath, Polly Ann , Tung, Nadine , Wolff, Antonio C. , Winer, Eric P. , Lin, Nancy U. , Pohlmann, Paula

Mayo Clinic

Journal of Clinical Oncology | March 12, 2019 | Volume: 37 | Issue: 13 | Pages: 1081-1089

10.1200/jco.18.01511 | PMID 30860945 Get It

PURPOSE Evidence-based treatments for metastatic, human epidermal growth factor receptor 2 (HER2)–positive breast cancer to the CNS are limited. We previously reported modest activity of neratinib monotherapy for HER2-positive breast cancer brain metastases. Here we report the results from additional study cohorts. PATIENTS AND METHODS Patients with measurable, progressive, HER2-positive brain metastases (92% after receiving CNS surgery and/or radiotherapy) received neratinib 240 mg orally once per day plus capecitabine 750 mg/m 2 twice per day for 14 days, then 7 days off. Lapatinib-naïve (cohort 3A) and lapatinib-treated (cohort 3B) patients were enrolled. If nine or more of 35 (cohort 3A) or three or more of 25 (cohort 3B) had CNS objective response rates (ORR), the drug combination would be deemed promising. The primary end point was composite CNS ORR in each cohort separately, requiring a reduction of 50% or more in the sum of target CNS lesion volumes without progression of nontarget lesions, new lesions, escalating steroids, progressive neurologic signs or symptoms, or non-CNS progression. RESULTS Forty-nine patients enrolled in cohorts 3A (n = 37) and 3B (n = 12; cohort closed for slow accrual). In cohort 3A, the composite CNS ORR = 49% (95% CI, 32% to 66%), and the CNS ORR in cohort 3B = 33% (95% CI, 10% to 65%). Median progression-free survival was 5.5 and 3.1 months in cohorts 3A and 3B, respectively; median survival was 13.3 and 15.1 months. Diarrhea was the most common grade 3 toxicity (29% in cohorts 3A and 3B). Neratinib plus capecitabine is active against refractory, HER2-positive breast cancer brain metastases, adding additional evidence that the efficacy of HER2-directed therapy in the brain is enhanced by chemotherapy. For optimal tolerance, efforts to minimize diarrhea are warranted.
DNA methylation in serum as an independent marker of outcome and treatment response in TBCRC 005: A prospective study in metastatic breast cancer (MBC) patients.
Fackler, Mary Jo , Lopez‐Bujanda, Zoila A. , Jeter, Stacie C., Sokoll, Lori J. , Cope, Leslie , Umbricht, Christopher B. , Euhus, David , Carpenter, John T., Storniolo, Anna Maria , Nanda, Rita , Lopez-Bujanda, Zoila A , Visvanathan, Kala , Zhang, Zhe , Lin, Nancy U. , Carey, Lisa A. , Ingle, James N. , Sukumar, Saraswati , Wolff, Antonio C.

Mayo Clinic

Journal of Clinical Oncology | March 8, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 518-518

10.1200/jco.2015.33.15_suppl.518 Get It

TBCRC 022: Phase II trial of neratinib for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer and brain metastases (BCBM).
Gelman, Rebecca , Krop, Ian E. , Melisko, Michelle , Agar, Nathalie Y.R. , Blackwell, Kimberly , Connolly, Roisín M. , Poznak, Catherine Van , Puhalla, Shannon, Ryabin, Nicole, Lawler, Elizabeth S, Ibrahim, Nuhad K. , Liu, Minetta C. , Agar, Nathalie Y R , Freedman, Rachel A. , Wefel, Jeffrey S. , Lowe, Alarice Cheng-Yi , Niravath, Polly Ann , Wolff, Antonio C. , Winer, Eric P. , Lin, Nancy U.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 528-528

10.1200/jco.2014.32.15_suppl.528 Get It

Whole-exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients (pts) treated with prior trastuzumab (T): A correlative analysis of TBCRC003.
Wagle, Nikhil , Richardson, Andrea L. , Forero‐Torres, Andres , Hobday, Timothy J. , Dees, Elizabeth Claire , Nanda, Rita , Rimawi, Mothaffar F. , Barry, William T., Gabriel, Stacey B., Garraway, Levi A. , Krop, Ian E. , Rimawi, Mothaffar , Lin, Nancy U. , Leshchiner, Ignaty , Mayer, Ingrid A. , Wolff, Antonio C. , Winer, Eric P.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 536-536

10.1200/jco.2014.32.15_suppl.536 Get It

Validation of RECIST 1.1 for use with cytotoxic agents and targeted cancer agents (TCA): Results of a RECIST Working Group analysis of a 50 clinical trials pooled individual patient database.
Isaac, Gaëlle, Bogaerts, Jan , Chen, Alice P. , Dancey, Janet, Ford, Robert, Gwyther, Steve J, Huang, Erich P. , Liu, Yan , Mandrekar, Sumithra J. , Schwartz, Lawrence H., Shankar, Lalitha , Therasse, Patrick, Group, RECIST Working, Litière, Saskia , Vries, Elisabeth G.E. de , Hoekstra, Otto S. , Lin, Nancy U. , Seymour, Lesley , Group, RECIST Working

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 2534-2534

10.1200/jco.2017.35.15_suppl.2534 Get It

2534 Background: The Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 were derived from an international collaborative effort supported by data from clinical trials (16 studies, 9147 patients) on cytotoxic chemotherapy (CT), providing a standard tool for response assessment. RECIST’s role has been questioned for TCA. Using a pooled individual patient database (IPD) from clinical trials performed by industry and cooperative groups, we assessed whether modifications to RECIST are required to evaluate antitumor activity of TCA. Methods: Data were collected from phase 2 and 3 clinical trials testing TCA in solid tumors. To study the occurrence of mixed responses, the variability of response of lesions within patients was studied. Furthermore, response was correlated with survival through landmark analyses and time dependent Cox models. Results: Clinical data were obtained from 23,259 patients, mainly with lung (36%), colorectal (28%) or breast cancer (11%). 15,620 patients (67%) received a TCA, mainly transduction or angiogenesis inhibitors, either as single agent (37%) or combined with other TCAs (7%) or CT (56%); 28% received CT only and 5% best supportive care or placebo. Within-patient variability reduced as the number of lesions used for response assessment increased, and did so similarly for TCAs (+/- CT) and CT. Mixed responses seemed to occur similarly across these treatment categories as well. Landmark analyses showed improving overall survival by % tumor shrinkage and a clear distinction between the effect of tumor shrinkage and progressive disease (PD) according to RECIST 1.1. This was confirmed by time dependent analysis. In addition target lesion growth showed no marked improvement in overall survival prediction over and above the other components of RECIST 1.1 PD (new lesions, non-target PD), regardless of treatment (TCA, CT or both) received. Similar results were seen focusing on major tumor types and classes of TCA. Conclusions: Using a large IPD dataset we demonstrated that RECIST 1.1 performs equally well for response assessment of TCA as for CT. No modifications are required.